Anticoagulation in continuous renal replacement therapies ( C R R T );Anticoagulação em terapias contínuas de substituição renal

Revista da Associacao Medica Brasileira

Volumn 53, Issue 5, 2007, Pages 451-455

  Garcés, Erwin Otero ^a   Victorino, Josué Almeida ^a   Veronese, Francisco Verisimo ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Anticoagulation; Continuous renal replacement therapies; Low molecular weight heparin; Trisodium citrate; Unfractioned heparin

Indexed keywords

EID: 36448952378     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302007000500023     Document Type: Review

References (35)

1. Uchino S, Kellum JA, Bellomo R, Doig G, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813-8.
2. Murray P, Hall J. Renal replacement therapy for acute renal Failure. Am J Respir Crit Care Med. 2000;162:777-81.
3. Bellomo R, Ronco C. Continuous haemoflitration in the intensive care unit. Crit Care. 2000;4:339-45.
4. Bellomo R, Metha R. Acute renal replacement in the intensive care unit: now and tomorrow. New Horizons. 1995;3:760-7.
5. Hanson G, Moist L. Acute renal failure in the ICU: assessing the utility of continuous renal replacement. J Crit Care. 2003;18:48-51.
6. Gainza F, Quintanilla N, Lampreabe I. Anticoagulación y accesos vasculares en las técnicas de depuración extracorpórea. In: Net A, Roglan A, editores. Depuración extrarrenal en el paciente grave. Philadelphia: Elsevirer-Masson; 2004. p.161-82.
7. Ricci Z, Ronco C, D'amico G, De Felice R, Rossi J, Bolgan I, et al. Practice patterns in the management of acute renal failure in the critically ill patients: an international survey. Nephrol Dial Transplant. 2006;21:690-6.
8. Levi M, Opal S. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222.
9. Oudemans-van Straaten HM. Anticoagulation in CRRT: systemic or regional. In: Vincent JL, editors. Yearbook of intensive care and emergency medicine. Berlin: Springer-Verlag; 2006. p.690-6.
10. Davenport A. Extracorporeal anticoagulation for intermittent and continuous form of renal replacement therapy in the intensive care unit. In: Murray P, Brady H, Hall J, editors. Intensive care in nephrology. Boca Raton: Taylor & Francis Group; 2006. p.165-80.
11. Foot C, Fraser J. So you need to start renal replacement therapy on your ICU patients. Current Anaest Crit Care. 2005;16:321-9.
12. Klingel R, Schaefer M, Schwarting A, Himmelsobach F, Altes U, Uhlenbusch-Körner I, et al. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and different modes of enoxaparin anticoagulation. Nephrol Dial Transplant. 2004;19:164-70.
13. Manns M, Singler M, Teehan B. Continuous renal replacement therapy: an update. Am J Kidney Dis. 1998;32:185-207.
14. Van de Weteirng J, Westendorp R, Van der Hoeven J, Stolk B, Feuth J, Chang P. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol. 1996;7:145-50.
15. Oudemans-van Straaten HM, Wester JP, De Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?. Intensive Care Med. 2006;134:188-202.
16. Thong C, Kam P. Heparin-induced thrombocytopenia. Curr Anaesth Crit Care. 2005;16:143-50.
17. Opal S. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med. 2000;28: S34-7.
18. Weitz J. Low-Molecular-Weight Heparins. N Engl J Med. 1997;337:688-98.
19. Aguilar D, Goldhaber S. Clinical uses of low-molecular weight heparins. Chest. 1999;115:1418-23.
20. Kani C, Marcantonis S, Nicolaou C, Maggina N. Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study. J Crit Care. 2006;21:79-84.
21. Collet JP, Montalescot G, Choussat R, Lison L, Ankri A. Enoxaparin in unstable angina patients with renal failure. Int J Cardiol. 2001;80:81-2.
22. Hulot J-S, Vantelon C, Urien S, Bouzamondo A, Mahé I, Annick A, et al. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Ther Drug Monit. 2004;26:305-10.
23. Farooq V, Hegarty J, Chandrasekar T, Lamerton E, Mitra S, Hougton J. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis. 2004;43:531-7.
24. Lim W, Dentali F, Eikelboom J, Crowther M. Meta-Analysis: low-molecular weight heparin and bleeding in patients with severe renal insuficiency. Ann Intern Med. 2006;144:673-84.
25. Reeves J, Cumming A, Gallagher L, Santamaria J. A controlled trial of low-molecular weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med. 1999;27:2224-8.
26. Pont A, Oudemans-van Straaten HM, Roozendaal K, Zandstra D. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Crit Care Med. 2000;28:421-5.
27. Lim W, Cook D, Crowther M. Safety and efficacy of low-molecular weight heparin for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol. 2004;15:3192-206.
28. Wynckel A, Bernieh B, Toupance O, N'Guyen P, Wong T, Lavaud S, et al. Guidelines to the use of enoxaparin in slow continuous hemodialysis. In: Siebert HG, Mann H, Stumvoll HK, editors. Continuous hemofiltration. Basel: Karger; 1991. v.93, p.221-4.
29. Alastair J, Wood M. Low-Molecular Weight Heparins. N Engl J Med. 1997;337:688-98.
30. Tolwani A, Campbell R, Schenk M, Allon M, Warnock G. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int. 2001;60:370-4.
31. Kutsongiannis D, Mayers I, Chi W, Gibney N. Regional citrate anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis. 2000;35:802-11.
32. Mehta R, McDonald B, Ward D. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38:976-81.
33. Tan H, Baldwin I, Bellomo R. Continuous venovenous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med. 2000;26:1652-7.
34. Veronese F, Losekann A, Rodrigues A, Balbinotto A, Thomé F, Agra H, et al. Diretrizes sobre métodos dialíticos na insuficiência renal aguda. In: Veronese F, editor. IX Jornada Gaúcha De Nefrologia e de Enfermagem em Nefrologia. Gramado; 2003.
35. Vargas Hein O, von Heymann C, Lipps M, Ziemer S, Ronco C, Neumayer H, et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med. 2001; 27: 673-9.